Therapeutic approaches which are effective in tumour cells resistant to conventional chemotherapy would be of value. An E1B 55 kDa-deleted adenovirus (ONYX-015) induces lysis in cells with mutant p53, although the specificity of these observations for different cell types is unclear. We have used a matched set of drug-resistant human ovarian tumour cell lines to examine the potential of ONYX-015 for preferential replication and lysis of drug-resistant ovarian tumour cells with documented alterations in p53 function. Marked preferential replication of ONYX-015 is observed after infection of mutant p53 transfectant and cisplatin-resistant derivatives, compared to the wild-type p53 expressing parental A2780 line. Infection causes increased cytopathic
Introduction
The acquisition of drug resistance is a major problem in the successful treatment of cancer. Ovarian cancer represents a relatively chemosensitive solid tumour, with responsiveness to a range of agents. Cisplatin is the mainstay of drug treatment and high rates of response are observed in primary ovarian cancer. 1 However, early disease recurrence, in initially responsive patients, is associated with resistance to further platinum therapy and 5 year survival rates among patients with advanced ovarian cancer are poor. Resistance to cisplatin is multifactorial, however, mutations in p53 and/or alterations in p53 expression leading to reduced DNA damage-induced apoptosis are associated with resistance to cisplatin-based chemotherapy in ovarian cancer. 2, 3 Thus, anticancer therapies which are effective in drug-resistant ovarian tumour cells with dysfunctional p53 would be clinically important.
It has been shown that an adenovirus lacking E1B, 55 kDa gene expression (ONYX-015) is severely limited in its replication in cells with wild-type p53 function. 4 However, this virus can replicate, leading to cell lysis, in at least some tumour cell types which lack p53 function. effects in vitro and inhibition of tumour growth in vivo of the drug-resistant derivatives, but not the parental line. In apparent contrast, increased apoptosis and reduced clonogenic survival is induced by ONYX-015 infection of the chemosensitive parental cell line. ONYX-015 induces increased proapoptotic BAX and reduced anti-apoptotic BCLX L in parental cells, but not in the resistant derivative A2780/cp70. We propose that induction of apoptosis is one factor which prevents ONYX-015 spread and cytolysis after infection of chemosensitive cells, while it is the failure to engage apoptosis in drugresistant cells that allows preferential viral replication, spread and cytolysis. Gene Therapy (2001) 8, 369-375.
Therefore, this could provide a potential antitumour agent which will induce cell lysis specifically in tumours lacking p53 function. ONYX-015 can confer increased survival of nude mice with human tumour xenografts that have dysfunctional p53. 5 However, others have investigated the association between ONYX-015 viral replication and p53 status in a variety of cell lines and have reported no association. 6, 7 Indeed, Hall et al 8 suggested that ONYX-015 induces cell death more efficiently in wildtype p53 containing cells, thus questioning the proposed selectivity of ONYX-015 for p53 deficient tumour cells. However, this study did not determine whether the mechanism of cell death was due to cytolysis induced by viral replication or virus-induced apoptosis. Mutant p53 cells were also killed at later time-points. In the present study, we have examined the ability of ONYX-015 and wild-type adenovirus to replicate, inhibit tumour cell growth and induce apoptosis in tumour cells of known p53 function. We have used matched lines selected for acquired resistance to cisplatin and mutant p53 transfectants which have previously been shown to have reduced DNA damage-induced apoptosis. [9] [10] [11] We show marked preferential replication of ONYX-015 in cisplatin-resistant lines with dysfunctional p53, compared with chemosensitive parental cells. Furthermore, ONYX-015 infection causes increased cytopathic effects in vitro and inhibition of tumour growth in vivo of drug-resistant derivatives compared with the parental line. However, we also demonstrate that infection of wild-type p53 expressing par-ental A2780 cells with ONYX-015 leads to initial induction of apoptosis and reduced cell survival. We propose that this may potentially inhibit a productive viral replication cycle, especially for defective viruses whose replication is already partially compromised such as ONYX-015.
Results and discussion
Replication of ONYX-015 and wild-type Ad2 adenovirus in A2780 and drug-resistant derivatives The human ovarian cell line A2780, derived from an untreated patient, has wild-type p53 sequence and expresses functional p53. 3 The role of p53 in sensitivity of A2780 to genotoxic agents is demonstrated by the increased resistance of dominant-negative mutant p53 transfectants to several anticancer agents, including ionising radiation, cisplatin and doxorubicin, as well as reduced apoptosis induced by such genotoxics. [10] [11] [12] Independent cisplatin-resistant derivatives of A2780 have been isolated which are up to four-fold resistant to cisplatin, show cross-resistance to multiple anticancer drugs, and have lost p53-associated functions, such as ionising radiation-induced G1 arrest and p21/CIP1 transcription, although retaining wild-type p53 gene sequence. 3 The drug-resistant lines have reduced DNA damage-induced apoptosis, which is associated with altered expression of apoptosis-related genes including BCL2, BAK, BCLX L and the mismatch repair gene hMLH1. 9, 13 Wild-type Ad2 adenovirus replicates efficiently in all the A2780-derived lines (Figure 1 ), although with a consistent trend for the drug-resistant lines to support more Ad2 viral replication. However, after infection with E1B-deleted ONYX-015, there is a very marked preferential replication in all the independently derived drug-resistant lines, compared with the wild-type p53 expressing parental cells (Figure 1 ). The effect of viral replication has been examined in one of the drug-resistant derivatives, A2780/cp70, compared with parental A2780 cells in detail (Table 1) . Adenovirus replication has been compared either by viral burst assays or hexon protein expression assays. Viral DNA expression assays were not used because previous studies have already shown that wild-type adenovirus and E1B 55 kDa-deleted adenoviruses produce equivalent amounts of viral DNA on infection yet only 20% of infected cells produce infectious virions with E1B 55 kDa-deleted adenoviruses.
14 This suggests that viral DNA is not an accurate measure of viral replication. In contrast, the viral burst assay is a measure over time of infectious virus in the cell populations and is therefore a good measure of viral replication and spread. The hexon protein expression assay is a measure of the proportion of cells expressing the late phase hexon protein. This protein is required for viral capsid formation and therefore indicates that new viral particles have been produced. Both assays show that wild-type (Ad2) virus replicates efficiently in both A2780 and A2780/cp70 lines, but that ONYX-015 replicates preferentially in the A2780/cp70 drug-resistant cells. Compared with the cisplatin-resistant cell lines, replication of ONYX-015 as measured by burst assay was attenuated by over two orders of magnitude in the parental A2780 cell line (Table 1 ). Both the burst assay and hexon protein expression assay showed a statistically significant difference for ONYX-015 between A2780 and A2780/cp70 (P Ͻ 0.05).
To exclude the possibility that these differences in replication were due to differences in infectivity, the ability of these cell lines to be infected was determined using Ad5CMVlacZ virus (a replication-defective virus, deleted in E1A and E1B sequences) which contains a lacZ reporter gene. 15 There was no significant difference in the percentage of cells which can be infected by this virus between the parental and resistant lines examined (Table 1) . Thus the differences in viral replication observed with ONYX-015 are not due to differences in the ability of the cells to be infected, but presumably in replication and spread within the cell population. Goodrum and Ornelles, 6 reported that replication of E1B-deleted adenoviruses was cell cycle dependent and was greater when cells infected were in the S phase of the cell cycle. We therefore determined the percentage of cells in S phase in cell lines A2780 and A2780/cp70 by cell cycle analysis of asynchronous growing cells. This showed 41% S phase fraction in A2780 cells compared with 49% in A2780/cp70 cells. Although this could account for some of the observed increase in replication seen in A2780/cp70, it would not account for the substantial increase as observed using burst assays and hexon protein assays.
Studies utilising genetically matched cell lines differing only in the p53 status have been used to determine if p53 status controls replication of E1B 55 kDa gene-deleted adenoviruses. 4, [6] [7] [8] However, these studies have produced considerable controversy. Using matched colon cancer cell lines Bischoff et al 4 reported reduced replication of ONYX-015 virus in the p53 transfectant cell line using burst assays as the measure of replication. In contrast, Hall et al 8 reported no difference in replication in the same cell lines, and a second matched pair of HT1080 cell lines, using cytopathic effect assays as their measure of replication. The authors, however, did not determine the mechanism of cell death, ie viral induced cytolysis versus apoptosis and did not produce a quantitative measure of viral replication. We therefore examined genetically matched cell lines of A2780 using burst assays, hexon protein expression assays as well as cytopathic effect assays. A2780 is an ovarian tumour cell line which expresses wild-type p53 and is dependent on p53 function for induction of apoptosis by genotoxic agents. 9, 10 We have examined the ability of wild-type and ONYX-015 virus to replicate and induce oncolysis of A2780 cells transfected with dominant negative mutant p53 (codon 143; Val to Ala) compared with vector alone transfectants. These dominant negative mutant transfectants of A2780 have previously been shown to have lost p53-associated functions, including transcriptional transactivation of target genes. 3, 12, 13 As shown in Table 1 , wild-type virus replicates in A2780 and mutant p53 transfectants, while ONYX-015 shows enhanced replication in the mutant p53 transfectants but not after infection of the vector alone and parental cell line. Again the ability of these cell lines to be infected was determined using an Ad5CMVlacZ virus which contains a lacZ reporter gene. 14 We found that there is no difference in the percent of cells which can be infected by this virus in the lines examined (Table  1) . Thus, mutant p53 transfectants and cisplatin-resistant derivatives of the human ovarian cell line A2780 which have lost p53 functions are more permissive for ONYX-015 replication than parental cells with intact p53 function.
Growth inhibition of drug-resistant derivatives
Infection of the cells with virus at a MOI (multiplicity of infection) of 10 p.f.u. per cell induced increased cell lysis (CPE: cytopathic effect) in all the cisplatin-resistant lines compared with the parental line (Table 1 and data not shown). The ability of virus to inhibit growth of tumours in nude mice was also examined. Intraperitoneal injection of ONYX-015 at a dose of 10 8 p.f.u. daily for 5 days leads to inhibition of intraperitoneal growth of A2780/cp70 cells in nude mice xenografts (none of four mice injected with A2780/cp70 cells formed tumours), whereas there was no effect on growth of A2780 as intraperitoneal xenoGene Therapy grafts (six of six mice positive for tumour growth). Mice injected with PBS instead of virus formed tumours in all cases.
Together, these data suggest that in cisplatin-resistant derivatives of a human ovarian cell line, there is increased replication of ONYX-015 and this leads to increased cell lysis (CPE) in vitro and inhibition of tumour growth in vivo compared with the parental chemosensitive cell line.
Induction of apoptosis by ONYX-015
Infection of A2780 cells with ONYX-015 causes a significantly greater reduction in the clonogenic survival of cells assayed 24 h after infection compared with infection of A2780/cp70 (Figure 2 ). This appears to contradict the in vivo and in vitro data described above which showed that A2780 cells are more resistant to virus-induced cell lysis than A2780/cp70. In order to examine the basis of these differences in clonogenicity and cell survival we examined the ability of the virus to induce apoptosis.
We have used TUNEL labeling ( Figure 3 ) to measure apoptosis induced by wild-type virus and ONYX-015 ( Figure 3) . 16 Both wild-type adenovirus and ONYX-015 are able to induce apoptosis in the chemosensitive A2780 cell line. Neither wild-type nor ONYX-015 are able to induce apoptosis in the drug-resistant A2780/cp70 line. The ability of ONYX-015 and wild-type adenovirus to induce apoptosis in chemosensitive A2780 cells and not in resistant A2780/cp70 has been confirmed by apoptotic morphology, PARP cleavage (data not shown) and BAX induction (Figure 4 ). This lack of apoptosis in A2780/cp70 would explain why viral replication is greater in this cell line as measured by burst and hexon assays. In A2780, wild-type adenovirus produces a viral burst as well as inducing apoptosis. Figure 3 illustrates TUNEL staining and hexon protein staining in this cell line. In cells infected with wild-type virus, we were able to show cells undergoing apoptosis yet still expressing adenoviral hexon protein, indicating replication was possible in cells undergoing apoptosis. This was not found in A2780 cells infected with ONYX-015. The most likely explanation for this is the more efficient replication of wild-type adenovirus compared with ONYX-015, ie in cells infected with ONYX-015, apoptosis is induced before replication can be completed. This would also explain why the viral burst of wild-type virus was fourfold greater in A2780/cp70 compared with A2780. The differences in virus-induced apoptosis would also explain the reduction in survival induced by ONYX-015 in A2780, as measured by colony-forming assays, and the higher surviving fraction after infection of A2780/cp70.
We examined the expression of proteins associated
Figure 3 Induction of apoptosis in A2780 cells infected with Ad2 and ONYX-015 at an MOI of 100 p.f.u. per cell measured by TUNEL staining (green). Hexon protein expression is shown in red.
with apoptosis in virally infected A2780 and A2780/cp70 cells ( Figure 4) . In A2780 cells, both wild-type Ad2 and ONYX-015 infection causes a concurrent reduction in the levels of the anti-apoptotic protein BCLX L and an increase in the pro-apoptotic protein BAX, but no changes in the drug-resistant derivative. The observation that both wild-type adenovirus and ONYX-015 could induce apoptosis in A2780 was unexpected since both viruses contain the potent anti-apoptotic protein E1B 19 kDa. 17 We examined expression of this protein in A2780 infected cells compared with A2780/cp70 infected cells and found expression of E1B 19 kDa protein to be much lower in A2780 after infection with ONYX-015 compared with A2780/cp70. This effect cannot be entirely due to differences in p53, since Turnell et al 18 showed no correlation between E1B 19 kDa and p53 status in a variety of p53 wild-type and p53-mutant cell lines infected with wild-type adenovirus and E1B-deleted adenoviruses. In addition, we have shown that wild-type adenovirus can induce apoptosis in A2780 even though this virus has the E1B 55 kDa protein which has been shown to prevent p53-mediated apoptosis by inducing degradation of p53 via the ubiquitin pathway. 19, 20 Expression of the adenoviral E1A protein as well as host cell p21, p53 proteins was also examined to determine if there was any correlation with apoptosis induction. Adenoviral E1A has previously been shown to induce p53 protein accumulation, which mediates apoptosis. 17 In A2780 and A2780/cp70, equivalent levels of E1A were observed after infection indicating this was not a factor ( Figure 4) . Infection of A2780 with ONYX-015 causes a dramatic increase in p53 protein, as previously described by Grand et al, 21 as well as genes transcriptionally activated by p53 such as p21 and BAX proteins. However, the maximal level of BAX expression
Figure 4 Western immunoblots of A2780 and A2780/cp70 cells infected with Ad2 and ONYX-015 at an MOI of 100 p.f.u. per cell. Expression of adenoviral proteins E1A, E1B 19 kDa and host cell p53, p21, BAX, BCLX L was determined at 0 h, 24 h and 72 h. Vinculin was used as a loading control in each cell line.
does not correlate with either the increase in p53 levels or the changes in p21, indicating that control of gene expression takes place at multiple levels in these cells. On the other hand, the levels of p21 and BAX remain unchanged in the drug-resistant A2780/cp70 line after infection. Wild-type Ad2 causes loss of p53 protein in both A2780 and A2780/cp70 72h after infection. The reduced p53 protein levels are presumably due to the presence of the E1B 55 kDa protein in Ad2 which has been shown to lead to p53 protein degradation. 19, 20 In A2780, both Ad2 and ONYX-015 initially induce p21 protein, but p21 expression later drops at 72 h after infection. In Ad2 infected cells this loss of p21 could be explained by the loss of p53 due to E1B 55 kDa-mediated degradation. However, in E1B 55 kDa-deleted ONYX-015 infected cells this cannot be the explanation since p53 levels are induced and remain high after virus infection. In this case, the loss of p21 may be due to caspase degradation of p21 during induction of apoptosis as reported previously or alternatively may be due to p53 transcriptional inhibition by the adenoviral protein E4ORF6. 22, 23 In conclusion, it is likely that several factors, both viral and host cells, are controlling apoptosis in adenoviral infected cells. Selective replication of ONYX-015 in cells with non-functional p53 can be explained in terms of two factors: (1) the ability of virus to induce apoptosis in wild-type p53 containing cells limiting virus replication and spread; (2) the slower replication of adenoviruses deleted in the E1B 55 kDa gene region. For delayed replicating viruses such as ONYX-015, cells which undergo virus-induced apoptosis will be non-permissive for viral replication and spread with no subsequent cytolysis of the cell population, while cells resistant to apoptosis will be permissive for replication leading to virus spread and Gene Therapy cytolysis. Goodrum and Ornelles have demonstrated that at least in certain cell types, the defect leading to poor virus yield in ONYX-015 infected cells lies distal to the replication of the viral DNA, again suggesting that E1B 55 kDa has multiple cellular functions, only some of which are related to p53 binding. 6 The results presented in this report suggest that part of the defect of ONYX-015 replication in A2780 cells, compared with the efficient replication in drug and apoptosis-resistant tumor cell variants, is due to the engagement of the apoptotic machinery specifically in the chemosensitive cells with wild-type p53 function at early times after virus infection. Whether this is the only mechanism that accounts for the difference in replication capacity, or additional properties related to the other cellular functions of E1B 55 kDa in RNA transport and protein synthesis, remains to be established. One prediction from our studies is that in addition to the status of p53, which is a known mediator of apoptosis, other determinants of apoptosis will also determine the efficacy of ONYX-015 replication and spread in tumour cells.
The gene expression alterations in the drug-resistant lines studied are relevant to the mechanisms of drug resistance which correlate with treatment failure in ovarian cancer patients. 2, 3 From a clinical standpoint, the data support the possibility that ONYX-015 may be a useful treatment modality for certain classes of tumours which have acquired resistance to the apoptosis-inducing effects of chemotherapeutic drugs or radiation, with or without concomitant mutations in the p53 gene. The progressive spread of the virus, and the accompanying oncolytic effects, should only take place in the apoptosisresistant tumour cells. Any toxicity in normal tissues is likely to be limited by the early death of the first infected cells, and there should be no transmission of active virus to adjacent normal cells. Indeed, a phase I clinical trial carried out in patients with recurrent head and neck cancer who were previously treated with chemotherapy and/or radiotherapy have demonstrated evidence of tumour response in infected tumours with no evidence for toxicity in normal cells adjacent to the injected tumours. 24 
Materials and methods

Cell lines
Characterisation and growth conditions of the ovarian adenocarcinoma cell lines A2780, its cisplatin-resistant derivatives and mutant p53 transfectants have been described previously.
3,13 A2780 has wild-type p53 gene sequence and function, while the resistant derivatives, such as A2780/cp70, have wild-type p53 gene sequence but have abrogated p53 function. 3, 13 The p53 sequence of exons 4 to 9 of A2780, A2780/cp70 and other resistant derivatives were confirmed by Oncormed Corporation (Gaitherburg, MD, USA) and all were shown to have wild-type sequence.
For clonogenic assays, cells were seeded at a density of 5 × 10 5 per 90-mm plate and infected with ONYX-015 at a multiplicity of infection (MOI) of 1, 10 and 100 p.f.u. per cell with a mock uninfected control plate for 90 min. After 24 h, cells were harvested, plated at a density of 10 3 per plate (five replicas for each MOI) and incubated for 10 days at 37°C to allow colony formation to occur. The colonies were stained with crystal violet and colonies greater than 50 cells counted using a colony counter. The mean colony count per MOI was calculated and expressed relative to the uninfected control.
Viruses ONYX-015 is a chimeric human group C adenovirus (Ad2 and Ad5) which has a deletion between nucleotides 2496 and 3323 in the E1B region encoding the 55 kDa protein. In addition, there is a C to T transition at position 2022 in E1B which generates a stop codon at the third codon position of the protein. These alterations eliminate the expression of the 55 kDa protein in ONYX-015 infected cells. 25 Ad5CMVlacZ is a non-replicating E1-deleted adenovirus in which the reporter construct lacZ has been inserted into the E1 region under the control of the CMV promotor. 15 All adenoviruses were grown on the human embryonic kidney cell line HEK293 which expresses the E1 region of Ad2 and band purified on a CsCl gradient. Stocks were stored at −70°C after addition of glycerol to a concentration of 50% vol/vol.
Plaque assays were performed to determine the quantity of infectious viral particles in viral stocks and burst assays. Briefly, plates were scraped into 0.5 ml of media and lysates prepared by three cycles of freezing and thawing. Serial dilutions on the lysates were titred on HEK293 cells.
Cytopathic effect (CPE) assay: Cells were grown to 70-90% confluence and then infected with either ONYX-015 or Ad2 for 90 min at MOI of 1 and 10 p.f.u. per cell. Plates were monitored for CPE and the assay terminated when total cytolysis was observed at MOI of 1 p.f.u. per cell with wild-type adenovirus.
Infectivity assays: Infectivity of cell lines to adenovirus was determined using the non-replicating E1-deleted adenovirus with a lacZ reporter construct under control of the CMV promotor. 15 Cell monolayers were grown to 70-90% confluence and then infected with Ad5CMVlacZ adenovirus at 10 p.f.u. per cell for 90 min. After 24 h and 48 h incubation, cells were fixed and stained with X-gal solution in the dark for 24 h at 37°C. The number of blue staining cells to total cells was measured in five separate random high power fields and the mean determined and expressed as a percentage.
Replication assays
Burst assay: Burst assays were used to determine the replication efficiency of ONYX-015 and wild-type Ad2 in infected cells. Cell monolayers were infected at a MOI of 10 p.f.u. per cell with either Ad2 or ONYX-015 for 90 min. At 4 h and 72 h after infection, cells were scraped into 0.5 ml of medium and lysates prepared by three cycles of freezing and thawing. Serial dilutions on the lysates were titred on HEK293 cells using the plaque assay. The burst ratio was expressed as the concentration of virus at 72 h divided by the concentration of virus at 4 h after infection.
Hexon protein expression assay: Cell monolayers were grown to 50% confluence on 90-mm plates. Plates were infected either with Ad2 at 10 p.f.u. per cell or ONYX-015 at 10 p.f.u. per cell. After 48 h incubation, the cells were fixed in ice-cold 70% ethanol, washed in PBS and then re-suspended in anti-hexon protein antibody (Chemicon, Temecula, CA, USA) at 1/1000 dilution in PBS for 1 h at 37°C. The cells were washed in PBS and then re-suspended in FITC-labelled anti-mouse IgG (Sigma, Poole, UK) at 1/40 dilution at room temperature for 30 min. Cells were washed in PBS, resuspended in propidium iodide solution (10 g/ml) for 30 min at room temperature, and analysed by flow cytometry. The percentage of FITC staining cells was determined for Ad2 and ONYX-015 infected cells using uninfected cells as a negative control for FITC. Each infection was determined three times and the mean percentage calculated.
Western analysis
Exponentially growing cells were infected with either wild-type Ad2 or ONYX-015 at an infectivity of 100 p.f.u. per cell and extracts examined by Western analysis. The following primary antibodies were used: p53 (mouse monoclonal DO-1; Oncogene Science, Cambridge, MA, USA); p21 (rabbit polyclonal sc-397; Santa Cruz Biotechnology, Santa Cruz, CA, USA); vinculin (mouse monoclonal VIN-11-1; Sigma); E1A (mouse monoclonal M73; Oncogene Science); E1B (19 kDa) (rat monoclonal; Oncogene Science; Bcl2 (mouse monoclonal; DAKO, Ely, UK); BCLX L (mouse monoclonal; Transduction Labs, Lexington, KY, USA); BAX (rabbit polyclonal; Pharmingen, San Diego, CA, USA); Bak (mouse monoclonal; Amersham, Amersham, UK).
Apoptosis detection by TUNEL staining
Cell monolayers of A2780 on 90-mm plates were grown to 50% confluence and then infected with Ad2 adenovirus or ONYX-015 at 100 p.f.u. per cell for 90 min. Nonabsorbed virus was removed after 90 min and then medium with 10% FCS added. After 0, 24 and 72 h cells (floating and adherent) were harvested by trypsinisation and then resuspended in medium. Cytospins were then made using 5 × 10 5 cells per slide. Cells were then fixed in 4% paraformaldehyde at RT for 30 min. Slides were washed in PBS and then permeabilised with 0.1% Triton X-100, 0.1% Na Citrate for 2 min at 4°C. The slides were then washed in PBS and then 50 l of TUNEL reagent (Boehringer Mannheim, Lewes, UK in situ cell death detection kit fluorescein) added to the slide and incubated for 1 h at 37°C in a humidified chamber in the dark. The cells were washed in PBS × 2 for 5 min each and then incubated with 100 l of anti-adenoviral hexon protein mouse monoclonal antibody (Chemicon) at 1/1000 dilution for 1 h at 37°C in a humidified chamber in the dark. After washing in PBS, 100 l of anti-mouse Texas Red was added at a dilution of 1/50 and the cells incubated for 1 h at 37°C in a humidified chamber in the dark. Slides were washed in PBS and then counterstained with DAPI/antifade solution. The slides were covered with coverslips and sealed with nail varnish. The slides were then examined by fluorescent microscopy. Apoptotic cells stained bright green, hexon positive expressing cells bright red, and uninfected cells blue with DAPI counterstain.
